NEW YORK (GenomeWeb) – CRISPR Therapeutics and Casebia Therapeutics, its joint venture with Bayer, have signed a licensing deal for a cell transfection platform from MaxCyte.

Under the terms of the agreement, CRISPR Therapeutics and Casebia will obtain non-exclusive rights to commercial use of MaxCyte's Flow Electroporation technology for use in developing CRISPR/Cas9-based therapies for hemoglobin deficiencies and severe combined immunodeficiency.

The firm will make undisclosed upfront, milestone, and sales-based payments.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.